查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1980194

生物製藥市場規模、佔有率、成長及全球產業分析：按類型、應用和地區的洞察，2026-2034年預測

Biopharmaceuticals Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

生物製藥市場的成長要素

受慢性病盛行率上升、人口老化以及生物製藥和先進治療方法的強勁創新推動，全球生物製藥市場持續穩定擴張。預計2025年市場規模將達到6,664.1億美元，從2026年的7,207.2億美元成長至2034年的1.41,148兆美元，2026年至2034年的年複合成長率（CAGR）為8.6%。

到2025年，北美在全球市場佔據主導地位，市場佔有率達到 50.37%，這得益於其健全的保險償付制度、較高的診斷率以及先進生物製藥的快速普及。

生物製藥是利用生物技術，以生物來源的原料為原料生產的複雜藥物。這些藥物包括蛋白質、單株抗體、核酸、疫苗、荷爾蒙以及細胞和基因療法。由於人口老化和慢性病負擔日益加重，全球對生物製藥的需求顯著成長。

新冠疫情的影響

新冠疫情期間，市場呈現強勁成長態勢。新冠疫苗和治療藥物的快速研發、核准和全球分發顯著推動了2021年的銷售成長。監管政策的靈活性和緊急核准也加快了產品上市速度。

自2023年以來，隨著 COVID-19 病例數量的下降，市場已轉向穩步成長，這得益於強大的候選藥物研發管線以及癌症、免疫學和罕見疾病領域核准數量的增加。

市場趨勢

新興地區強勁的管道建設

亞太地區正崛起為臨床試驗中心，佔全球臨床活動的近50%（Cytel，2023）。光是中國就佔該地區I期臨床試驗的近40%。一個主要趨勢是，中國生物技術公司擴大將早期癌症治療技術授權給全球製藥公司。

CAR-T療法研發管線中的候選藥物數量激增。截至2023年3月，ClinicalTrials.gov網站列出了443個CAR-T療法研發管線候選藥物，而2012年僅有12個。隨著先進治療方法獲得監管部門核准的增加，競爭格局重塑。

市場成長要素

慢性病盛行率上升

慢性病給全球健康帶來沉重負擔。根據世界衛生組織（WHO，2023）統計，每年有4,100萬人死於非傳染性疾病，佔全球死亡總數的74%。診斷率的提高和公眾意識的增強推動對創新生物製藥的需求。

單株抗體的核准增加

單株抗體仍然是主要的成長要素。2020年至2021年間，監管機構核准了97種單株抗體，此外還有基因療法、荷爾蒙和疫苗。癌症和自體免疫疾病治療藥物的加速核准繼續推動市場擴張。

抑制因子

高昂的藥物研發和治療成本

生物製藥的研發需要大量資金。根據世界衛生組織（WHO）2022年的估計，研發新藥的成本在4,340萬美元到42億美元之間。

此外，CAR-T療法等先進治療方法極為昂貴。例如，一個療程的CAR-T療法費用約為47.5萬美元。高昂的價格可能導致某些地區患者難以獲得這些療法，並延緩其推廣應用。

市場區隔分析

依類型

市場區隔將產品分為免疫調節劑、疫苗、荷爾蒙、酵素和其他。

  • 2024年，免疫調節劑佔據市場主導地位，在單株抗體和細胞激素療法核准的推動下，預計到2026年，免疫調節劑將佔據 54.01%的市場佔有率。
  • 在常規免疫計劃和新疫苗核准的支持下，到2024年，疫苗將佔第二大佔有率。
  • 荷爾蒙類藥物市場的成長主要受糖尿病盛行率上升的推動。截至2023年，全球已有5.37億人患有糖尿病。
  • 酵素和感染疾病物的成長穩定，但速度相對較慢。

依用途

應用領域包括腫瘤學、循環系統、呼吸內科、免疫學和神經病學。

  • 腫瘤領域在2024年成為市場成長的主要驅動力，預計2026年佔據45.3%的市場佔有率。主要原因是癌症發生率的上升。
  • 呼吸系統領域佔據了第二大市場。
  • 隨著針對自體免疫疾病的在研藥物核准，免疫學領域預計將以第二高的年複合成長率成長。
  • 神經病學和循環系統正呈現穩定但緩慢的成長。

依通路

這些細分市場包括醫院藥局、藥局/零售藥局和網路藥局。

  • 到2024年，醫院藥局將主導向住院病人施用先進生物製藥的市場。
  • 預計到2026年，藥局和零售藥局將佔市場佔有率的35.87%。
  • 由於數位化和宅配服務的進步，預計線上藥局將以最高的年複合成長率成長。

區域趨勢

北美洲

北美維持領先地位，2025年市場規模達3,356.5億美元。預計到2026年，美國市場規模將達到3,458億美元。完善的醫保償付機制和抗癌藥物的廣泛普及是推動該地區成長的主要因素。

歐洲

歐洲佔據了相當大的市場。預計到2026年，英國市場規模將達到305.5億美元，德國市場規模預計將達481.6億美元。政府資金和戰略夥伴關係支持市場擴張。

亞太地區

預計亞太地區將以最高的年複合成長率成長。到2026年：

  • 日本：173.4億美元
  • 中國：410.7億美元
  • 印度：79.6億美元

臨床試驗數量的增加、監管核准的增加以及患者意識的提高推動該地區的成長。

世界其他地區

由於基礎設施的限制，拉丁美洲、中東和非洲地區的年複合成長率預計將相對較低，但醫療保健系統的改善逐步支持擴張。

主要企業

全球市場主要企業包括以下幾家：

  • Pfizer Inc.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Eli Lilly
  • Sanofi
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • GSK plc
  • Takeda Pharmaceutical Company Limited

在新冠肺炎疫情期間，Pfizer Inc.憑藉強勁的疫苗銷售佔據了市場主導地位。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 主要疾病流行情形：依主要國家分類，2025年
  • 新產品發布：按主要企業分類
  • 關鍵產業趨勢 - 併購與合作
  • 主要國家的監管狀況
  • 主要企業管道分析
  • 新冠疫情對市場的影響

第5章 2021-2034年全球生物製藥市場分析、洞察與預測

  • 市場分析、洞察與預測：依類型
    • 免疫調節劑
      • 單株抗體
      • 細胞激素
      • 干擾素
      • 其他
    • 酵素
      • 水解酵素
      • 解離酶
      • 氧化還原酶
      • 其他
    • 疫苗
      • 重組/組合/次單元
      • 失活
      • 減毒活病毒疫苗
      • 類毒素
    • 荷爾蒙
      • 人體生長荷爾蒙
      • 胰島素
      • 甲狀腺刺激素
      • 其他
    • 其他
  • 市場分析、洞察與預測：依應用領域分類
    • 循環系統
    • 腫瘤學
    • 呼吸系統
    • 免疫學
    • 神經病學
    • 其他
  • 市場分析、洞察與預測：依通路分類
    • 醫院藥房
    • 藥局和零售藥房
    • 網路藥房
  • 市場分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美生物製藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲生物製藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太生物製藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章 拉丁美洲生物製藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章 中東和非洲生物製藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • Pfizer Inc.
    • AbbVie Inc.
    • Bristol-Myers Squibb Company
    • Johnson & Johnson Services, Inc.
    • Bayer AG
    • Lilly
    • Sanofi
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • GSK plc
    • Takeda Pharmaceutical Company Limited.
Product Code: FBI106928

Growth Factors of biopharmaceuticals Market

The global biopharmaceuticals market continues to expand steadily, supported by rising chronic disease prevalence, increasing geriatric population, and strong innovation in biologics and advanced therapies. The market was valued at USD 666.41 billion in 2025 and is projected to grow from USD 720.72 billion in 2026 to USD 1,411.48 billion by 2034, registering a CAGR of 8.6% during 2026-2034.

In 2025, North America dominated the global market with a 50.37% share, driven by strong reimbursement systems, high diagnosis rates, and rapid adoption of advanced biologics.

Biopharmaceuticals are complex medicines derived from biological sources using biotechnology. These include proteins, monoclonal antibodies, nucleic acids, vaccines, hormones, and cell and gene therapies. Growing aging populations and the rising burden of chronic diseases are significantly increasing global demand.

COVID-19 Impact

The market experienced strong positive growth during the COVID-19 pandemic. The rapid development, approval, and global distribution of COVID-19 vaccines and therapeutics significantly boosted revenues in 2021. Regulatory flexibility and emergency approvals accelerated product launches.

From 2023 onward, as COVID-19 cases declined, the market transitioned toward steady growth driven by robust pipeline candidates and increasing approvals across oncology, immunology, and rare diseases.

Market Trends

Strong Pipeline Development in Emerging Regions

Asia Pacific has emerged as a clinical trial hub, accounting for nearly 50% of global clinical activity (Cytel, 2023). China alone contributes nearly 40% of Phase I trials in the region. Increasing licensing of early-stage cancer therapies from Chinese biotech firms to global pharmaceutical companies is a key trend.

The number of CAR-T therapy pipeline candidates has surged significantly. In March 2023, 443 CAR-T pipeline candidates were listed on ClinicalTrials.gov, compared to only 12 in 2012. Growing regulatory approvals for advanced therapies are reshaping the competitive landscape.

Market Growth Drivers

Rising Prevalence of Chronic Diseases

Chronic diseases are a major global health burden. According to WHO (2023), 41 million deaths annually are attributed to non-communicable diseases, accounting for 74% of global deaths. Rising diagnosis rates and awareness programs are increasing demand for innovative biologics.

Increasing Approvals for Monoclonal Antibodies

Monoclonal antibodies remain a major growth driver. Between 2020 and 2021, regulatory agencies approved 97 monoclonal antibodies, along with gene therapies, hormones, and vaccines. Accelerated approvals for oncology and autoimmune treatments continue to fuel market expansion.

Restraining Factors

High Drug Development and Treatment Costs

Biopharmaceutical development is capital-intensive. WHO (2022) estimates the cost of developing a new drug ranges between USD 43.4 million and USD 4.2 billion.

Additionally, advanced therapies such as CAR-T treatments are highly expensive. For example, one treatment cycle of CAR-T therapy can cost approximately USD 475,000. High pricing may limit accessibility and slow adoption in certain regions.

Market Segmentation Analysis

By Type

The market is segmented into immunomodulators, vaccines, hormones, enzymes, and others.

  • Immunomodulators dominated in 2024 and are projected to hold 54.01% share in 2026, driven by monoclonal antibody approvals and cytokine therapies.
  • Vaccines held the second-largest share in 2024, supported by routine immunization programs and new vaccine approvals.
  • The hormone segment growth is driven by rising diabetes prevalence. In 2023, 537 million people were living with diabetes globally.
  • Enzymes and anti-infectives contribute steady but comparatively moderate growth.

By Application

Applications include oncology, cardiology, respiratory, immunology, neurology, and others.

  • Oncology dominated the market in 2024 and is projected to account for 45.3% share in 2026. Rising cancer incidence is a primary factor.
  • The respiratory segment held the second-largest share.
  • Immunology is expected to grow at the second-highest CAGR due to pipeline approvals for autoimmune diseases.
  • Neurology and cardiology show moderate but steady growth.

By Distribution Channel

Segments include hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

  • Hospital pharmacies dominated in 2024 due to inpatient administration of advanced biologics.
  • Drug stores & retail pharmacies are projected to contribute 35.87% share in 2026.
  • Online pharmacies are expected to grow at the highest CAGR due to digital adoption and doorstep delivery services.

Regional Insights

North America

North America generated USD 335.65 billion in 2025, maintaining its leadership. The U.S. market is projected to reach USD 345.8 billion by 2026. Strong reimbursement frameworks and high oncology drug adoption drive regional growth.

Europe

Europe holds a substantial market share. The UK market is projected to reach USD 30.55 billion by 2026, while Germany is expected to reach USD 48.16 billion by 2026. Government funding and strategic partnerships support expansion.

Asia Pacific

Asia Pacific is projected to grow at the highest CAGR. By 2026:

  • Japan: USD 17.34 billion
  • China: USD 41.07 billion
  • India: USD 7.96 billion

Rising clinical trials, regulatory approvals, and growing patient awareness fuel regional growth.

Rest of the World

Latin America and the Middle East & Africa are expected to grow at a comparatively lower CAGR due to infrastructure limitations but improving healthcare systems are gradually supporting expansion.

Key Industry Players

Leading companies shaping the global market include:

  • Pfizer Inc.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Eli Lilly
  • Sanofi
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • GSK plc
  • Takeda Pharmaceutical Company Limited

Pfizer Inc. dominated the market during the COVID-19 period due to strong vaccine sales performance.

Conclusion

The global biopharmaceuticals market is projected to expand from USD 666.41 billion in 2025 to USD 1,411.48 billion by 2034, growing at a CAGR of 8.6% during 2026-2034. Rising chronic disease prevalence, increasing monoclonal antibody approvals, and robust pipeline development-particularly in oncology and immunology-are key growth drivers. While high development and treatment costs remain a challenge, expanding clinical research, technological innovation, and strong regional investments, especially in North America and Asia Pacific, are expected to sustain long-term market growth.

Segmentation By Type

  • Immunomodulators
    • Monoclonal Antibodies
    • Cytokines
    • Interferons
    • Others
  • Enzymes
    • Hyrdolases
    • Lyases
    • Oxidoreductases
    • Others
  • Vaccines
    • Recombinant/Conjugate/Subunit
    • Inactivated
    • Live Attenuated
    • Toxoid
  • Hormones
    • Human Growth Hormones
    • Insulin
    • Thyroid Stimulating Hormones
    • Others
  • Others

By Application

  • Cardiology
  • Oncology
  • Respiratory
  • Immunology
  • Neurology
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Type, Application, Distribution Channel, and Country)
    • U.S. (By Application)
    • Canada (By Application)
  • Europe (By Type, Application, Distribution Channel, Country, and Country/Sub-Region)
    • U.K. (By Application)
    • Germany (By Application)
    • France (By Application)
    • Italy (By Application)
    • Spain (By Application)
    • Scandinavia (By Application)
    • Rest of Europe (By Application)
  • Asia Pacific (By Type, Application, Distribution Channel, and Country/Sub-Region)
    • China (By Application)
    • India (By Application)
    • Japan (By Application)
    • Australia (By Application)
    • Southeast Asia (By Application)
    • Rest of Asia Pacific (By Application)
  • Latin America (By Type, Application, Distribution Channel, and Country/Sub-Region)
    • Brazil (By Application)
    • Mexico (By Application)
    • Rest of Latin America (By Application)
  • Middle East & Africa (By Type, Application, Distribution Channel, and Country/Sub-Region)
    • GCC (By Application)
    • South Africa (By Application)
  • Rest of Middle East & Africa (By Application)

Table of Content

1. Introduction

  • 1.1. Market Scope
  • 1.2. Market Segmentation
  • 1.3. Market Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries/Regions, 2025
  • 4.2. New Product Launches, By Key Players
  • 4.3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.4. Regulatory Scenario, By Key Countries/Regions
  • 4.5. Pipeline Analysis, By Key Players
  • 4.6. Impact of COVID-19 on the Market

5. Global Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Immunomodulators
      • 5.1.1.1. Monoclonal Antibodies
      • 5.1.1.2. Cytokines
      • 5.1.1.3. Interferons
      • 5.1.1.4. Others
    • 5.1.2. Enzymes
      • 5.1.2.1. Hyrdolases
      • 5.1.2.2. Lyases
      • 5.1.2.3. Oxidoreductases
      • 5.1.2.4. Others
    • 5.1.3. Vaccines
      • 5.1.3.1. Recombinant/Conjugate/Subunit
      • 5.1.3.2. Inactivated
      • 5.1.3.3. Live Attenuated
      • 5.1.3.4. Toxoid
    • 5.1.4. Hormones
      • 5.1.4.1. Human Growth Hormones
      • 5.1.4.2. Insulin
      • 5.1.4.3. Thyroid Stimulating Hormones
      • 5.1.4.4. Others
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Cardiology
    • 5.2.2. Oncology
    • 5.2.3. Respiratory
    • 5.2.4. Immunology
    • 5.2.5. Neurology
    • 5.2.6. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Drug Stores & Retail Pharmacies
    • 5.3.3. Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Immunomodulators
      • 6.1.1.1. Monoclonal Antibodies
      • 6.1.1.2. Cytokines
      • 6.1.1.3. Interferons
      • 6.1.1.4. Others
    • 6.1.2. Enzymes
      • 6.1.2.1. Hyrdolases
      • 6.1.2.2. Lyases
      • 6.1.2.3. Oxidoreductases
      • 6.1.2.4. Others
    • 6.1.3. Vaccines
      • 6.1.3.1. Recombinant/Conjugate/Subunit
      • 6.1.3.2. Inactivated
      • 6.1.3.3. Live Attenuated
      • 6.1.3.4. Toxoid
    • 6.1.4. Hormones
      • 6.1.4.1. Human Growth Hormones
      • 6.1.4.2. Insulin
      • 6.1.4.3. Thyroid Stimulating Hormones
      • 6.1.4.4. Others
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Cardiology
    • 6.2.2. Oncology
    • 6.2.3. Respiratory
    • 6.2.4. Immunology
    • 6.2.5. Neurology
    • 6.2.6. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Drug Stores & Retail Pharmacies
    • 6.3.3. Online Pharmacies
    • 6.3.4. Other Facilities
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Application
    • 6.4.2. Canada
      • 6.4.2.1. By Application

7. Europe Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Immunomodulators
      • 7.1.1.1. Monoclonal Antibodies
      • 7.1.1.2. Cytokines
      • 7.1.1.3. Interferons
      • 7.1.1.4. Others
    • 7.1.2. Enzymes
      • 7.1.2.1. Hyrdolases
      • 7.1.2.2. Lyases
      • 7.1.2.3. Oxidoreductases
      • 7.1.2.4. Others
    • 7.1.3. Vaccines
      • 7.1.3.1. Recombinant/Conjugate/Subunit
      • 7.1.3.2. Inactivated
      • 7.1.3.3. Live Attenuated
      • 7.1.3.4. Toxoid
    • 7.1.4. Hormones
      • 7.1.4.1. Human Growth Hormones
      • 7.1.4.2. Insulin
      • 7.1.4.3. Thyroid Stimulating Hormones
      • 7.1.4.4. Others
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Cardiology
    • 7.2.2. Oncology
    • 7.2.3. Respiratory
    • 7.2.4. Immunology
    • 7.2.5. Neurology
    • 7.2.6. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Drug Stores & Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
      • 7.4.1.1. By Application
    • 7.4.2. Germany
      • 7.4.2.1. By Application
    • 7.4.3. France
      • 7.4.3.1. By Application
    • 7.4.4. Italy
      • 7.4.4.1. By Application
    • 7.4.5. Spain
      • 7.4.5.1. By Application
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Application
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Application

8. Asia Pacific Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Immunomodulators
      • 8.1.1.1. Monoclonal Antibodies
      • 8.1.1.2. Cytokines
      • 8.1.1.3. Interferons
      • 8.1.1.4. Others
    • 8.1.2. Enzymes
      • 8.1.2.1. Hyrdolases
      • 8.1.2.2. Lyases
      • 8.1.2.3. Oxidoreductases
      • 8.1.2.4. Others
    • 8.1.3. Vaccines
      • 8.1.3.1. Recombinant/Conjugate/Subunit
      • 8.1.3.2. Inactivated
      • 8.1.3.3. Live Attenuated
      • 8.1.3.4. Toxoid
    • 8.1.4. Hormones
      • 8.1.4.1. Human Growth Hormones
      • 8.1.4.2. Insulin
      • 8.1.4.3. Thyroid Stimulating Hormones
      • 8.1.4.4. Others
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Cardiology
    • 8.2.2. Oncology
    • 8.2.3. Respiratory
    • 8.2.4. Immunology
    • 8.2.5. Neurology
    • 8.2.6. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Drug Stores & Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. China
      • 8.4.1.1. By Application
    • 8.4.2. India
      • 8.4.2.1. By Application
    • 8.4.3. Japan
      • 8.4.3.1. By Application
    • 8.4.4. Australia
      • 8.4.4.1. By Application
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Application
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Application

9. Latin America Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Immunomodulators
      • 9.1.1.1. Monoclonal Antibodies
      • 9.1.1.2. Cytokines
      • 9.1.1.3. Interferons
      • 9.1.1.4. Others
    • 9.1.2. Enzymes
      • 9.1.2.1. Hyrdolases
      • 9.1.2.2. Lyases
      • 9.1.2.3. Oxidoreductases
      • 9.1.2.4. Others
    • 9.1.3. Vaccines
      • 9.1.3.1. Recombinant/Conjugate/Subunit
      • 9.1.3.2. Inactivated
      • 9.1.3.3. Live Attenuated
      • 9.1.3.4. Toxoid
    • 9.1.4. Hormones
      • 9.1.4.1. Human Growth Hormones
      • 9.1.4.2. Insulin
      • 9.1.4.3. Thyroid Stimulating Hormones
      • 9.1.4.4. Others
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Cardiology
    • 9.2.2. Oncology
    • 9.2.3. Respiratory
    • 9.2.4. Immunology
    • 9.2.5. Neurology
    • 9.2.6. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Drug Stores & Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
      • 9.4.1.1. By Application
    • 9.4.2. Mexico
      • 9.4.2.1. By Application
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Application

10. Middle East & Africa Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Immunomodulators
      • 10.1.1.1. Monoclonal Antibodies
      • 10.1.1.2. Cytokines
      • 10.1.1.3. Interferons
      • 10.1.1.4. Others
    • 10.1.2. Enzymes
      • 10.1.2.1. Hyrdolases
      • 10.1.2.2. Lyases
      • 10.1.2.3. Oxidoreductases
      • 10.1.2.4. Others
    • 10.1.3. Vaccines
      • 10.1.3.1. Recombinant/Conjugate/Subunit
      • 10.1.3.2. Inactivated
      • 10.1.3.3. Live Attenuated
      • 10.1.3.4. Toxoid
        • 10.1.3.4.1. Hormones
          • 10.1.3.4.1.1. Human Growth Hormones
          • 10.1.3.4.1.2. Insulin
          • 10.1.3.4.1.3. Thyroid Stimulating Hormones
          • 10.1.3.4.1.4. Others
        • 10.1.3.4.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Cardiology
    • 10.2.2. Oncology
    • 10.2.3. Respiratory
    • 10.2.4. Immunology
    • 10.2.5. Neurology
    • 10.2.6. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Drug Stores & Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
      • 10.4.1.1. By Application
    • 10.4.2. South Africa
      • 10.4.2.1. By Application
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Application

11. Competitive Analysis

  • 11.1. Global Market Share Analysis ( 2025)
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. AbbVie Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Bristol-Myers Squibb Company
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Johnson & Johnson Services, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Bayer AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Lilly
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Sanofi
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Merck & Co., Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. F. Hoffmann-La Roche Ltd
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Novartis AG
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. GSK plc
      • 11.2.11.1. Overview
      • 11.2.11.2. Products & Services
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)
    • 11.2.12. Takeda Pharmaceutical Company Limited.
      • 11.2.12.1. Overview
      • 11.2.12.2. Products & Services
      • 11.2.12.3. SWOT Analysis
      • 11.2.12.4. Recent Developments
      • 11.2.12.5. Strategies
      • 11.2.12.6. Financials (Based on Availability)

List of Tables

  • Table 01: Global Biopharmaceuticals Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 02: Global Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 03: Global Biopharmaceuticals Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 04: Global Biopharmaceuticals Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 05: North America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 06: North America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 07: North America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 08: North America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 09: U.S. Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 10: Canada Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 11: Europe Biopharmaceuticals Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 12: Europe Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 13: Europe Biopharmaceuticals Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 14: Europe Biopharmaceuticals Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 15: U.K. Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 16: Germany Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 17: France Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 18: Italy Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 19: Spain Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 20: Scandinavia Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 21: Rest of Europe Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 22: Asia Pacific Biopharmaceuticals Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 23: Asia Pacific Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 24: Asia Pacific Biopharmaceuticals Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 25: Asia Pacific Biopharmaceuticals Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: China Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 27: India Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 28: Japan Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 29: Australia Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 30: Southeast Asia Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 31: Rest of Asia Pacific Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 32: Latin America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 33: Latin America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 34: Latin America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 35: Latin America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Brazil Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 37: Mexico Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 38: Rest of Latin America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 39: Middle East & Africa Biopharmaceuticals Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 40: Middle East & Africa Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 41: Middle East & Africa Biopharmaceuticals Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 42: Middle East & Africa Biopharmaceuticals Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 43: GCC Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 44: South Africa Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 45: Rest of Middle East & Africa Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034

List of Figures

  • Figure 01: Global Biopharmaceuticals Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 02: Global Biopharmaceuticals Market Value Share (%), by Type, 2025 & 2034
  • Figure 03: Global Biopharmaceuticals Market Value Share (%), by Application, 2025 & 2034
  • Figure 04: Global Biopharmaceuticals Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 05: Global Biopharmaceuticals Market Value (USD billion), by Region, 2025 & 2034
  • Figure 06: North America Biopharmaceuticals Market Value (USD billion), By Type, 2025 & 2034
  • Figure 07: North America Biopharmaceuticals Market Value Share (%), By Type, 2025
  • Figure 08: North America Biopharmaceuticals Market Value (USD billion), By Application, 2025 & 2034
  • Figure 09: North America Biopharmaceuticals Market Value Share (%), By Application, 2025
  • Figure 10: North America Biopharmaceuticals Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 11: North America Biopharmaceuticals Market Value Share (%), By Distribution Channel, 2025
  • Figure 12: North America Biopharmaceuticals Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Biopharmaceuticals Market Value Share (%), By Country, 2025
  • Figure 14: Europe Biopharmaceuticals Market Value (USD billion), By Type, 2025 & 2034
  • Figure 15: Europe Biopharmaceuticals Market Value Share (%), By Type, 2025
  • Figure 16: Europe Biopharmaceuticals Market Value (USD billion), By Application, 2025 & 2034
  • Figure 17: Europe Biopharmaceuticals Market Value Share (%), By Application, 2025
  • Figure 18: Europe Biopharmaceuticals Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 19: Europe Biopharmaceuticals Market Value Share (%), By Distribution Channel, 2025
  • Figure 20: Europe Biopharmaceuticals Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Biopharmaceuticals Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Biopharmaceuticals Market Value (USD billion), By Type, 2025 & 2034
  • Figure 23: Asia Pacific Biopharmaceuticals Market Value Share (%), By Type, 2025
  • Figure 24: Asia Pacific Biopharmaceuticals Market Value (USD billion), By Application, 2025 & 2034
  • Figure 25: Asia Pacific Biopharmaceuticals Market Value Share (%), By Application, 2025
  • Figure 26: Asia Pacific Biopharmaceuticals Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Biopharmaceuticals Market Value Share (%), By Distribution Channel, 2025
  • Figure 28: Asia Pacific Biopharmaceuticals Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Biopharmaceuticals Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Biopharmaceuticals Market Value (USD billion), By Type, 2025 & 2034
  • Figure 31: Latin America Biopharmaceuticals Market Value Share (%), By Type, 2025
  • Figure 32: Latin America Biopharmaceuticals Market Value (USD billion), By Application, 2025 & 2034
  • Figure 33: Latin America Biopharmaceuticals Market Value Share (%), By Application, 2025
  • Figure 34: Latin America Biopharmaceuticals Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Biopharmaceuticals Market Value Share (%), By Distribution Channel, 2025
  • Figure 36: Latin America Biopharmaceuticals Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Biopharmaceuticals Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Biopharmaceuticals Market Value (USD billion), By Type, 2025 & 2034
  • Figure 39: Middle East & Africa Biopharmaceuticals Market Value Share (%), By Type, 2025
  • Figure 40: Middle East & Africa Biopharmaceuticals Market Value (USD billion), By Application, 2025 & 2034
  • Figure 41: Middle East & Africa Biopharmaceuticals Market Value Share (%), By Application, 2025
  • Figure 42: Middle East & Africa Biopharmaceuticals Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Biopharmaceuticals Market Value Share (%), By Distribution Channel, 2025
  • Figure 44: Middle East & Africa Biopharmaceuticals Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Biopharmaceuticals Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Biopharmaceuticals Market Share (%), By Company, 2025